CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic ...

- SELECT trial of vopratelimab in combination with pimivalimab versus pimivalimab alone did not meet its primary endpoint of mean tumor change averaged over 9 and 18 weeks- - Encouraging trends in ...

According to the authors, these results extend the clinical relevance of semaglutide beyond its established cardiovascular protective effects. By lowering the frequency and duration of hospital stays, ...

A multicenter randomized phase III trial of customized chemotherapy versus standard of care for first-line treatment of elderly patients with advanced non-small cell lung cancer (EPIC). This is an ...

- SELECT trial of vopratelimab in combination with pimivalimab versus pimivalimab alone did not meet its primary endpoint of mean tumor change averaged over 9 and 18 weeks - - Encouraging trends in ...

Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced strong and ...

In this prespecified exploratory analysis of the SELECT randomized clinical trial, the trial cohort had a high rate of hospital admissions. Treatment with once-weekly semaglutide was associated with ...

This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I. This abstract does not include a full text component.

Simple initiatives to help people select lower-calorie options when ordering takeaways in delivery apps could help tackle the obesity epidemic, suggest three randomised trials being presented at this ...